Endometrial carcinoma diagnosis in the molecular era: a review and new considerations for low- to middle-income countries
Keywords:
endometrial carcinoma, molecular era, low- to middle-income countriesAbstract
The incidence of endometrial carcinoma (EC) has seen a steady increase globally over the years. According to the Cancer Association of South Africa (CANSA), EC is the fourth most common carcinoma in women. The publication of the International Federation of Gynecology and Obstetrics (FIGO) 2023 staging for the management of EC has incorporated molecular EC subtyping in addition to commonly used histopathological diagnosis. The four molecular subtypes of EC defined by The Cancer Genome Atlas (TCGA) research group have been renamed: 1) POLEmut (POLE ultramutated), 2) p53abn (p53-abnormal, copy number high), 3) MMRd (mismatch repair deficient, microsatellite instability hypermutated), and 4) NSMP (no specific molecular profile, copy number low). The molecular profiling of EC by TCGA used whole exome sequencing with determination of somatic copy number alterations (SCNA) on multiple platforms, which may prove costly in low- to middle-income countries (LMIC). The Proactive Molecular Risk Classifier of Endometrial Cancer (ProMisE) aims to validate TCGA results and investigate the correlation between the traditional clinicopathological prognostic features using a simple decision tree focused on immunohistochemistry and simple molecular testing. In a LMIC healthcare facility, the two molecular subtypes that can be tested using surrogates in immunohistochemical stains are p53 and MMRd, MLH1, PMS2, MSH2, and MSH6. There is no surrogate at present to test for POLE mutation; however, there is QPOLE – a low-cost quantitative multiplex polymerase chain reaction (PCR) that can detect the 11 most common and pathogenic POLE mutations. The use of a flow diagram in the daily clinical practice of patients with EC should be considered in LMIC. Future translational research in determining the cost-effectiveness of preoperative molecular pathology testing for treatment planning and risk stratification of patients is needed in resource-limited settings.
Downloads
Published
Issue
Section
License
South African Journal of Gynaecological Oncology (SAJGO) Copyright is held by South African Society of Gynaecologic Oncology (SASGO). Copyright of the articles is held by the authors. The work is licensed under a Creative Commons Attribution-Non-Commercial Works 4.0 South Africa License (CC BY NC). Material submitted for publication in the SAJGO is accepted provided it has not been published elsewhere. The SAJGO does not hold itself responsible for statements made by the authors. The opinions expressed in this publication are those of the authors. They do no purport to reflect the opinions or views of SASGO or its members.